The Abbott baby formula manufacturing facility in Michigan that has been shuttered since February is “likely” to resume operations in two weeks, according to the U.S. Food and Drug Administration.
Under fire from parents and politicians, President Joe Biden’s administration on Monday is expected to announce an agreement to reopen the largest domestic manufacturing plant of infant formula as well as ease import rules to allow supplies from overseas, amid a nationwide shortage.
A consent decree between Abbott and the FDA paving the way for reopening the plant is “forthcoming,” said Brian Deese, director of the White House’s National Economic Council.
On Monday, FDA chief Dr. Robert Califf told “Today” that his department has been working closely with Abbott, which on Friday said the plant would be back up and running in two weeks, subject to FDA approval.
“I am very comfortable with what they said about two weeks,” Dr. Califf told host Savannah Guthrie.
“That’s entirely within the realm of possibility and, in fact, I think quite likely,” he added regarding Abbott’s proposed timeline.
Califf said the FDA would investigate the plant to ensure that it is free of contamination and that formula produced at the facility contains all of the ingredients that make it a suitable substitute for breast milk.
He also dismissed claims that the national baby formula shortage, which has worsened in past weeks, could last through the end of the year.
“We don’t expect it to last until the end of the year by any means. We’re taking a number of measures including getting all the manufacturers to step up,” he said.
He added that the FDA would release more details on the “path forward” by the end of the day Monday.
— The Associated Press contributed to this report
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
